The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000759392p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
21/05/2026
Date registered
Help: Date registered
25/06/2026
Date last updated
Help: Date last updated
25/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
25/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Matrix Matters: Yolk-Driven Effects for Exercise Recovery

Scientific title
Matrix Matters: Yolk-Driven effects on muscle soreness for Exercise Recovery among regularly active participants

Additional trial identifiers [1] 317353 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Muscle Recovery 342014 0
Condition category
Condition code
Musculoskeletal 338095 338095 0 0
Normal musculoskeletal and cartilage development and function

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The three acute dietary interventions are as follows:
• Whole eggs (WE): e.g., 3 whole eggs (volume will be standardised across participants to provide 18 g protein from eggs), prepared as a standardised omelette with vegetables, toast and 300ml of water and no added fat.
• Egg whites (EW): egg-white equivalent to match protein target (e.g., ~250–300 mL liquid whites standardised to provide 18 g of protein), prepared in the same recipe format as above with vegetable oil added to match fat content above.
• Whey protein (WP): flavoured shake providing the same protein dose along with toast as above with water provided to match fluid intake above and vegetable oil added to match fat across conditions.


As well as the treatment arms described here, participants will also complete a standardised exercise protocol as the Exercise Induced Muscle Damage (EIMD) intervention. This exercise is comprised of 30 sets of 10 reps of maximal eccentric leg extensions on an isokinetic dynamometer. Intensity is defined as maximal on each repetition. This exercise intervention is to be administered and supervised by members of the research team with extensive prior experience in similar exercise interventions (Dr Urwin, Dr Convit, Dr Hamilton).

The dietary interventions will commence immediately following the conclusion of the EIMD, and all food is to be consumed within a 30 minute period. The 30 minute ingestion period also applies to the subsequent days within each treatment (i.e. the three days following EIMD). The dietary intervention is to be designed by a dietitian within our team (Dr Convit), and delivered by members of the research team with extensive experience in acute feeding studies (Dr Convit, Dr Urwin).

Adherence to the first meal is confirmed by the research team. Adherence to subsequent days is confirmed by the participants.

Each trial is separated by a 14 day washout period. With limb alternation, washout between limb repeats is equal to a minimum of 31 days (two 14 days washouts, plus the 3 day intervention on the alternate limb).

For a sub set of participants (n = 10, equal numbers M and F), we will we will perform amino-acid profiling (liquid chromatography-tandem mass spectrometry; LC-MS/MS) and fatty-acid profiling (GC-MS) at baseline (pre-meal) and every 10-20mins for the 3 h post-meal window during each period. This involves collection of venous blood samples via cannulation at the prescribed intervals, during which time participants stay seated and complete sedentary activities only (such as reading, watching TV). Cannulation and sample collection is to be completed by phlebotomy trained and experienced members of the research team (Dr Urwin, Dr Convit). Venous blood samples collected will be centrifuged to collect plasma, which will be frozen for later analysis.

This sub set of participants is selected as the first 5 male and the first 5 female participants to ensure adherence to the planned sample size.
Intervention code [1] 334145 0
Treatment: Other
Description of the comparator or control
The whey protein treatment is to be considered the comparator treatment.
Control group
Active

Outcomes
Primary outcome [1] 345495 0
VAS Muscle Soreness (0-100 mm)
Timepoint [1] 345495 0
4h, 48h, 72h post intervention for each dietary intervention.
Secondary outcome [1] 461911 0
Isometric Maximal Voluntary Contraction
Timepoint [1] 461911 0
4h, 48h, 72h post intervention for each dietary intervention.
Secondary outcome [2] 461912 0
Creatine kinase
Timepoint [2] 461912 0
4h, 48h, 72h post intervention for each dietary intervention.
Secondary outcome [3] 462468 0
Lactate dehydrogenase
Timepoint [3] 462468 0
4h, 48h, 72h post intervention for each dietary intervention.
Secondary outcome [4] 462470 0
Amino acid profiles, consisting of individual amino acid concentrations (Alanine, Arginine, Aspartic acid, Cysteine, Glutamic acid, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tyrosine, Valine, Tryptophan) and composite values that sum several of the individual amino acids: branched-chain amino acids (Isoleucine + Leucine + Valine), essential amino acids (Histidine + Isoleucine + Leucine + Lysine + Methionine + Phenylalanine + Threonine + Valine + Tryptophan), non-essential amino acids (Alanine + Arginine + Aspartic acid + Cysteine + Glutamic acid + Glycine + Proline + Serine + Tyrosine), total amino acids (sum of all quantified amino acids).
Timepoint [4] 462470 0
At baseline (pre-meal) and every 10-20mins for the 3 h post-meal window during each dietary intervention
Secondary outcome [5] 462471 0
Fatty acid profiles (Total saturated fatty acids, Total monounsaturated fatty acids, Total polyunsaturated fatty acids, Total omega-3 fatty acids, Total omega-6 fatty acids, Omega-6 to omega-3 ratio, Total fatty acids).
Timepoint [5] 462471 0
At baseline (pre-meal) and every 10-20mins for the 3 h post-meal window during each dietary intervention

Eligibility
Key inclusion criteria
Healthy adults (18–30 y), mixed-sex, who are active (exercise at least 3 times/week for at least the previous 6 months but not strength trained) and can attend all lab sessions and willing to limit egg consumption to only the eggs provided to them during the trial.
Minimum age
18 Years
Maximum age
30 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Egg allergy/intolerance; inability to suspend egg consumption or recovery-affecting supplements (e.g., creatine, high-dose omega-3) during the study; regular NSAID/analgesic use that cannot be paused; significant musculoskeletal, cardiovascular, or metabolic disease; shift work; pregnancy/lactation; current high-dose protein supplementation (>40 g/day from powders) unwilling to standardise.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation of order using computer generated sequences.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Analyses will use linear mixed-effects models with fixed effects for treatment (WE/EW/WP), period (1–3), and sequence (1–6), and a random participant intercept. The primary estimand is the treatment contrast in VAS at 48 h (when pain tends to peak post EIMD); supportive analyses will model repeated time points (4/48/72 h) with an appropriate covariance. Pairwise tests will be WE–EW (hierarchically primary), WE–WP, and EW–WP with Bonferroni adjustment. We will present effect sizes with 95% CIs and interpret against the 14-mm MCID (superiority if CI excludes 0 and exceeds MCID; practical equivalence if the 95% CI lies within ±14 mm). Missing outcome data will be handled under missing at random assumptions via mixed models.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321928 0
Commercial sector/Industry
Name [1] 321928 0
Australian Eggs
Country [1] 321928 0
Australia
Primary sponsor type
University
Name
Deakin University
Address
Country
Australia
Secondary sponsor category [1] 324796 0
Commercial sector/Industry
Name [1] 324796 0
Australian Eggs
Address [1] 324796 0
Country [1] 324796 0
Australia

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 320464 0
Deakin University Human Research Ethics Committee (DUHREC)
Ethics committee address [1] 320464 0
Ethics committee country [1] 320464 0
Australia
Date submitted for ethics approval [1] 320464 0
01/12/2026
Approval date [1] 320464 0
Ethics approval number [1] 320464 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150554 0
Dr Charles Urwin
Address 150554 0
Deakin University, 221 Burwood Highway, Burwood, 3125, Victoria
Country 150554 0
Australia
Phone 150554 0
+61 3 924 68958
Fax 150554 0
Email 150554 0
Contact person for public queries
Name 150555 0
Charles Urwin
Address 150555 0
Deakin University, 221 Burwood Highway, Burwood, 3125, Victoria
Country 150555 0
Australia
Phone 150555 0
+61 3 924 68958
Fax 150555 0
Email 150555 0
Contact person for scientific queries
Name 150556 0
Charles Urwin
Address 150556 0
Deakin University, 221 Burwood Highway, Burwood, 3125, Victoria
Country 150556 0
Australia
Phone 150556 0
+61 3 924 68958
Fax 150556 0
Email 150556 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.